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Abstract
Background Although factors associated with an
increased risk of recurrence after liver transplantation for
hepatocellular carcinoma (HCC) have been extensively
studied, the history of patients with a post-transplant
recurrence is poorly known.
Methods Patients experiencing a post-transplant HCC
recurrence from 1996 to 2011 in two transplant programs
were included. Demographic, transplant, and post-recur-
rence variables were assessed.
Results Thirty patients experienced an HCC recurrence–
22 men and 8 women with a mean age of 55 ± 6 years.
Sixteen (53 %) were outside the Milan criteria at the time
of transplantation. Most recurrences (60 %) appeared
within the first 18 months after transplantation, ranging
between 1.7 and 109 months (median 14.2 months). Mean
post-recurrence survival was 33 ± 31 months. On univar-
iate analysis, total tumor volume (TTV; p = 0.047),
microvascular invasion (p = 0.011), and time from trans-
plant to recurrence (p = 0.001) predicted post-recurrence
survival. On multivariate analysis, both time from trans-
plant to recurrence (p = 0.001) and history of rejection
(p = 0.043), but not the location of the recurrence or the
type of recurrence treatment, predicted post-recurrence
survival.
Conclusion This study suggests that patients with early
post-transplant HCC recurrence have worse outcomes.
Those with a history of graft rejection have better surviv-
als, possibly due to more active anti-cancer immunity.
Keywords Hepatocellular carcinoma  Recurrence 
Survival
Introduction
Liver transplantation is the best treatment option for
patients with early hepatocellular carcinoma (HCC). It
offers better outcomes than competing strategies, with
expected five-year survivals of 70–90 % [1–3]. Despite
these good results, some 10 % of patients experience a
post-transplant HCC recurrence, which leads to death in
most cases.
The risk of post-transplant recurrence has been exten-
sively studied, with the proposal of various candidate
selection criteria including a wide range of extension
compared with the classical Milan criteria [1–3]. Overall, it
appears that both the tumor burden (assessed as the total
tumor volume [TTV] or the maximum tumor size) and
biological factors, such as alpha fetoprotein (AFP), best
predict outcome, and these factors can help maintain low
rates of post-transplant recurrence.
While recurrence is a relatively rare event, only a few
publications with limited sample sizes have looked at this
specific group of patients. Careful study of this group holds
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the potential for improvement in their management. The
present study assesses the history and risk factors predict-
ing survival after post-transplant HCC recurrence in a large
cohort combining patients at two centers with similar
transplant candidate selection criteria and outcomes.
Patients and methods
Patient inclusion
This study retrospectively assessed liver transplant recipi-
ents with a post-transplant HCC recurrence established by
typical imaging and/or biopsy. Only patients transplanted
after the publication of the Milan criteria were included
(December 1996–April 2010) [1]. None of them had an
incidental HCC on the explanted liver. Patients were
transplanted at the University of Geneva, Switzerland, or at
the University of Alberta, Edmonton, Canada. The study
was approved by the institutional ethics review board
committees of both institutions.
Transplant characteristics and recurrence assessment
Both programs used extended inclusion criteria. At the
University of Geneva, patients within Milan or downstaged
to Milan were all considered for transplantation. At the
University of Alberta, selection criteria were a single HCC
B7.5 cm in diameter, or multiple tumors (without number
restriction) B5 cm. Patients with a biopsy-proven poorly
differentiated HCC larger than 5 cm were excluded in the
initial Alberta series. Beginning in 2010 (Geneva) and
2007 (Alberta), a score based on a combination of TTV
(B115 cm3) and AFP (B400 ng/ml) was used for candidate
selection. With the use of such a score, similar outcomes
can be achieved within Milan, and beyond Milan, but
within the TTV/AFP score [2, 4, 5]. The TTV was obtained
by adding the maximum volume of each HCC computed
based on the formula (4/3)pr3, calculated using the maxi-
mum radius of each tumor. Of note, the TTV does not
include any strict limit in the number of HCCs, and two
patients with 20 lesions have been included (both alive and
well 3 and 6 years after transplantation). In the present
study, pathological HCC characteristics were used for TTV
calculation. All candidates with large liver vessel HCC
invasion or with extrahepatic disease were excluded.
Beginning in 2002 (Geneva) and 1996 (Alberta), immu-
nosuppression was sirolimus-based starting from the time
of transplantation [6, 7].
Post-transplant monitoring of recurrence was performed
by thoraco-abdominal computed tomography (CT) scan
every 6 months for the first 3 years and by ultrasonography
(US) every 6 months thereafter. After the third post-
transplant year, extrahepatic recurrences were detected on
the basis of symptoms.
Analyses and statistical methods
The demographics of patients with recurrence were asses-
sed and factors predicting post-recurrence survival deter-
mined. Rejection was designated to include biopsy-proven
rejections and events requiring treatment for rejection
(even if not biopsy-proven). Prospectively established
databases were used retrospectively (OTTR; Hickman-
Kenyon Systems, Omaha, NE, USA). Survival was ana-
lyzed by the Kaplan–Meier method and differences
between groups tested by log-rank or Cox tests. Multivar-
iate analysis using a Cox proportional hazards model was
used for the assessment of the prognostic factors reaching
p values of at least 0.2 on univariate analysis. Further tests
included the v2 for categorical variables and t-test for
continuous variables. A standard alpha level of 0.05 indi-
cated statistical significance. Results are expressed as
means ± standard deviation (SD). Analyses were con-
ducted using SPSS 15.0 (SPSS, Chicago, IL, USA).
Results
Demographics
During the study period, 234 liver transplantations were
performed for HCC and 30 recipients experienced a
recurrence (overall rate of recurrence: 12.8 %; 12/97,
12.4 % in Geneva and 18/137, 13.1 % in Alberta). The
recipients with recurrence were eight women and 22 men,
with a mean age of 55 ± 6 years (Table 1). The most
frequent underlying liver disease was linked to hepatitis C
virus (HCV) infection. Pre-transplant local HCC treatment
included transarterial chemoembolization (n = 14), sur-
gery (n = 6), percutaneous alcohol injection (n = 4),
radio-frequency ablation (n = 3), and cryo-ablation
(n = 1). All patients with recurrence had received whole
liver grafts, except for one live liver graft recipient. Mean
follow up after recurrence was 32.9 ± 31.2 months
[median 18.7 (1.7–110.2) months].
In an effort to understand the cause of recurrence, the
profile of each patient with recurrence was assessed inde-
pendently. Half of the patients were outside the Milan
criteria, five (17 %) presented a TTV [115 cm3 and four
(13 %) an AFP [400 ng/ml. In addition, nine patients
(30 %) showed a macrovascular invasion on pathology, 18
(60 %) a microvascular invasion and 11 (37 %) a poorly
differentiated HCC. These tumor factors could explain all
recurrences except four. In these four patients, smoking
was the only factor potentially contributing to recurrence.
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While none of the patients with recurrence had been
actively smoking at the time of transplantation, these four
patients all had a past history of heavy smoking, at 15, 20,
30, and 30 pack-years. Of all the studied patients, 16
patients (53 %) had a history of smoking (mean 26.5 ± 10
pack-years, range 10–50 pack-years). Despite aggressive
pre-transplant anti-smoking policies and support programs
at both centers, nine recipients were still actively smoking
at the time of transplantation.
Recurrence characteristics
Recurrence appeared as early as 1.7 and up to 109 months
after transplantation (mean 24 ± 28 months). Most of
them occurred within 18 months (median 14.2 months,
Fig. 1a), while recurrence was an unusual event after
36 months (5/30 or 16.7 %). Recurrence most often
involved the liver, lungs, and bones, and was multiple in
eight patients (27 %, Table 2). Of note, the patient with the
earliest recurrence, 1.7 months after transplantation, pre-
sented with multiple poorly differentiated HCC metastases
in the liver graft.
Recurrence was treated by surgery in 20 % of patients
(Table 2), but most underwent loco-regional (10 %) or pal-
liative (70 %) treatments. Mean post-recurrence survival was
33 ± 31 months (median survival 18.8 ± 6.8 months), with
deaths happening between 1.7 and 110.2 months after recur-
rence (Fig. 1b).
Factors predicting survival after post-transplant HCC
recurrence
On univariate assessment, post-recurrence survival was
predicted by tumor factors (TTV and microvascular inva-
sion) and the time between transplantation and recurrence
(Table 3). On multivariate analysis, the time between
transplant and recurrence [hazard ratio; HR 0.88 (95%
confidence interval; CI 0.81–0.95), p = 0.001] and the
occurrence of a rejection during the first 6 months after
transplantation [HR 3.46 (95% CI 1.04–11.56), p = 0.043]
predicted post-recurrence survival (Fig. 2). In order to
better estimate the impact of these two variables, inde-
pendent survival curves were drawn (using the median time
between transplant and recurrence of 14.2 months as cut-
off (Table 2). A late diagnosis of recurrence and the
Table 1 Patient and tumor characteristics at transplantation
Patients (number) 30
Mean age (years ± SD) 55 ± 6
Gender Female 8/male 22
Cause of liver disease (%)
HCV (±alcohol, ±HBV) 23 (77)
HBV 5 (17)
Alcohol 1 (3)
Alpha 1 anti-trypsin 1 (3)
MELD score 12 ± 6.5
Number of HCCs 4.3 ± 7.8
Largest HCC (cm ± SD) 3.8 ± 1.8
Total tumor volume (cm3 ± SD) 58 ± 69
Patients with total tumor volume C115 cm3 5 (17)
Alpha fetoprotein (AFP; ng/ml ± SD) 295 ± 711
Patients with AFP C400 ng/ml 4 (13)
Macrovascular invasion (%) 9 (30)
HCC grade 1/2/3 (%) 2 (8)/13 (50)/11 (42)
Within Milan criteria (%) 15 (50)
mTOR inhibitor-based immunosuppression 19 (63)
HCC hepatocellular carcinoma, HCV hepatitis C virus infection, HBV
hepatitis B virus infection, MELD model for end-stage liver disease,
mTOR mammalian target of rapamycin
Fig. 1 a Histogram showing the distribution of the time between
transplantation and recurrence in the 30 studied patients. b Overall
post-recurrence survival (median survival 18.8 ± 6.8 months). HCC
Hepatocellular carcinoma
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occurrence of a rejection during the first 6 months after
transplantation were both associated with longer survivals.
Of note, the extent of the recurrence (single vs. multiple
sites) and the type of recurrence treatment did not alter
survival. Two patients were put on sorafenib after
recurrence.
Discussion
The present study suggests that the time of appearance of a
post-transplant HCC recurrence has a strong impact on
survival and that the immune status (history of rejection)
may also play a role.
A post-transplant recurrence can appear in two situa-
tions; firstly, when an extra-hepatic metastasis has been
missed (or was not detectable) during the pre-transplant
work-up. Secondly, a recurrence can also be the conse-
quence of circulating HCC cells engrafting and growing in
a target organ during the peri-transplant period [8]. Given
the higher original cancer load of the first mechanism, such
recurrences are expected to appear earlier after transplan-
tation. These two mechanisms may help explain the
Table 2 HCC recurrence characteristics
Time from transplant to recurrence (months ± SD) 24 ± 28
Patients alive with recurrence (%) 3 (10)






Multiple locations (%) 8 (27)
Treatment of recurrence
Medical/palliation 21 (70)
Loco-regional (including TACE, PEI) 3 (10)
Surgical resection 6 (20)
TACE transarterial chemo-embolisation, PEI percutaneous ethanol
injection
Table 3 Factors predicting survival after post-transplant HCC recurrence
Variablesa Univariate analysis Multivariate analysisa
HR (95 % CI) p HR (95 % CI) p
Age at transplant 1.02 (0.96–1.09) 0.55
Cause of liver disease
HCV (±alcohol, ±HBV) 1
HBV 2.66 (0.33–21.21) 0.36
Smoking (pack-years) 1.01 (0.97–1.04) 0.74
Transplant characteristics
Year of transplantation 0.55 (0.20–1.47) 0.22
Pre-transplant local HCC treatment (yes vs. no) 0.55 (0.20–1.47) 0.23
MELD at transplant 1.01 (0.96–1.05) 0.88
Number of HCCs 1.05 (0.98–1.11) 0.22
Total tumor volume 1.01 (1.000–1.012) 0.047
Alpha fetoprotein 1 (0.999–1.001) 0.93
Microvascular invasion (yes vs. no) 3.07 (1.29–7.28) 0.011
HCC grade (1 or 2 vs. 3) 0.76 (0.32–1.79) 0.53
Within Milan criteria (within vs. beyond) 0.56 (0.26–1.23) 0.15
mTOR inhibitor-based immunosuppression (yes vs. no) 0.98 (0.45–2.15) 0.96
Rejection from 0 to 6 months post-transplant (yes vs. no) 1.9 (0.75–4.83) 0.18 3.46 (1.04–11.56) 0.043
Recurrence characteristics and treatment
Time from transplant to recurrence 0.91 (0.86–0.96) 0.001 0.88 (0.81–0.95) 0.001
Location of recurrence
Liver 1
Lung 1.01 (0.22–4.69) 0.99
Other 1.12 (0.23–5.44) 0.89
Surgical resection (yes vs. no) 1.31 (0.44–3.9) 0.62
HR hazard ratio, CI confidence interval, HCV hepatitis C virus infection, HBV hepatitis B virus infection
a Significant variables
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observed bimodal distribution of recurrences, with most of
them appearing during the first 18 months and some, more
indolent, diagnosed up to 10 years after transplantation
(Fig. 1a).
Along the same line, patients diagnosed with early
recurrence may not only have a higher original cancer load,
but may also have a more aggressive biology. Perhaps as a
result of these factors, these patients have a significantly
lower life expectancy. This observation reinforces previous
studies suggesting that the time between transplant and
recurrence is key in predicting the outcome after recur-
rence, with worse survival rates when recurrence is diag-
nosed within 12 months from transplantation [9–11]. Such
data are important to guide the management of and to
better inform patients.
The observed overall post-recurrence survival was close to
3 years on average (median survival 18.8 ± 6.8 months),
which is similar to previously reported data after whole organ
liver transplantation (survivals ranging from 8 to 24 months in
average [9–13]).
In the present study, the occurrence of a rejection during
the first 6 months after transplantation was also an inde-
pendent predictor of post-recurrence survival. This finding
may reflect the use of a less profound immunosuppression
combination, more active immunity, and potentially the
presence of active cytotoxic immune cells in patients
demonstrating a rejection. These factors illustrate the yin-
yang situation of liver transplantation for hepatocellular
carcinoma (HCC), which is performed in the presence of
both donor (allogeneic) and cancer antigens. While the
allogeneic immunity should be decreased, the anti-cancer
one should be preserved and potentially enhanced. Along
this line, stronger immune depletion (as assessed by low
ATP production by peripheral blood mononuclear cells,
determined using the ImmuKnow test, Cylex, Columbia,
MD) has been associated with a higher risk of post-trans-
plant HCC recurrence [14]. Similarly, the risk of HCC
recurrence has been strongly correlated with the level of
calcineurin inhibitor immunosuppression and with the use
of antilymphocyte antibody induction [15, 16]. While fur-
ther validation is mandatory, such data would promote the
use of milder immunosuppression combinations in patients
undergoing transplantation for HCC.
Surgery has been reported to significantly improve the
post-recurrence survival of patients with local recurrence
[9, 10, 12, 17, 18]. While this was not the case in the
present study (potentially due to the relatively low sample
size), a surgical resection should be attempted whenever
feasible, as supported by the report of a recent consensus
conference [19]. Of note, liver re-transplantation is cur-
rently recognized as not appropriate after post-transplant
HCC recurrence [19].
Although randomized data are still pending, several
studies suggest an anti-cancer effect and better post-trans-
plant survivals with the use of mammalian target of rapa-
mycin (mTOR) inhibitors, and patients may be put on such
drugs when a recurrence occurs [6, 7, 19, 20]. Of note, the
observed lack of improved post-recurrence survival with
mTOR inhibitors in the present study may be related to the
high patient heterogeneity and to the relatively low sample
size.
Of note, most of the patients in the present study pre-
sented risk factors for post-transplantation recurrence, but
four had small HCCs and low AFP levels. In these four
patients, smoking was the only contributory factor. While
this observation clearly requires further exploration, it
reinforces the need to promote and support cessation of
smoking prior to liver transplantation for HCC. As a
reminder, smoking has been associated with the occurrence









Fig. 2 Post-recurrence survival according to the occurrence of a
rejection during the first 6 months after transplantation (a) and
according to the time between transplantation and the recurrence (b)
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demonstrating a past or current smoking history [21].
Active smoking has been reported to be more strongly
associated with HCC than obesity or heavy alcohol intake
(odds ratio of 4.55 vs. 2.13 and 1.77) [21]. Similarly,
smoking has been associated with an increased risk of
colon cancer metastasis and recurrence after surgery, even
in past smokers [22, 23].
The present study suggests that early recurrence and the
use of more profound immunosuppression result in worse
post-recurrence outcomes. Such data can be used to better
manage and inform recipients of liver transplantation for
HCC prior to and after a potential recurrence.
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